413 related articles for article (PubMed ID: 27167192)
21. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
22. Clinical and biological significance of transcription termination factor, RNA polymerase I in human liver hepatocellular carcinoma.
Komatsu H; Iguchi T; Ueda M; Nambara S; Saito T; Hirata H; Sakimura S; Takano Y; Uchi R; Shinden Y; Eguchi H; Masuda T; Sugimachi K; Eguchi H; Doki Y; Mori M; Mimori K
Oncol Rep; 2016 Apr; 35(4):2073-80. PubMed ID: 26821084
[TBL] [Abstract][Full Text] [Related]
23. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth.
Wang C; Wang X; Su Z; Fei H; Liu X; Pan Q
Oncol Rep; 2015 Oct; 34(4):1708-16. PubMed ID: 26239364
[TBL] [Abstract][Full Text] [Related]
24. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
Peng YY; He YH; Chen C; Xu T; Li L; Ni MM; Meng XM; Huang C; Li J
Cancer Lett; 2016 Jun; 376(1):10-21. PubMed ID: 26975630
[TBL] [Abstract][Full Text] [Related]
25. The role of AIM2 in human hepatocellular carcinoma and its clinical significance.
Zheng P; Xiao W; Zhang J; Zheng X; Jiang J
Pathol Res Pract; 2023 May; 245():154454. PubMed ID: 37060822
[TBL] [Abstract][Full Text] [Related]
26. Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IκB.
Fang L; Sun J; Pan Z; Song Y; Zhong L; Zhang Y; Liu Y; Zheng X; Huang P
Am J Physiol Gastrointest Liver Physiol; 2017 Aug; 313(2):G150-G156. PubMed ID: 28526689
[TBL] [Abstract][Full Text] [Related]
27. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
Longerich T
Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
[TBL] [Abstract][Full Text] [Related]
28.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
[TBL] [Abstract][Full Text] [Related]
30. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.
Guo P; Ma X; Zhao W; Huai W; Li T; Qiu Y; Zhang Y; Han L
Oncogene; 2018 Jan; 37(4):478-488. PubMed ID: 28967907
[TBL] [Abstract][Full Text] [Related]
31. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
32. ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma.
Wu YJ; Ko BS; Liang SM; Lu YJ; Jan YJ; Jiang SS; Shyue SK; Chen L; Liou JY
Cell Death Dis; 2019 May; 10(6):408. PubMed ID: 31138789
[TBL] [Abstract][Full Text] [Related]
33. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
[TBL] [Abstract][Full Text] [Related]
34. Promotion of glycolysis by HOTAIR through GLUT1 upregulation via mTOR signaling.
Wei S; Fan Q; Yang L; Zhang X; Ma Y; Zong Z; Hua X; Su D; Sun H; Li H; Liu Z
Oncol Rep; 2017 Sep; 38(3):1902-1908. PubMed ID: 28731193
[TBL] [Abstract][Full Text] [Related]
35. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
Wei S; Xiong M; Zhan DQ; Liang BY; Wang YY; Gutmann DH; Huang ZY; Chen XP
Carcinogenesis; 2012 Mar; 33(3):538-47. PubMed ID: 22226916
[TBL] [Abstract][Full Text] [Related]
36. HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma.
Huang JL; Ren TY; Cao SW; Zheng SH; Hu XM; Hu YW; Lin L; Chen J; Zheng L; Wang Q
Oncotarget; 2015 Oct; 6(32):33791-804. PubMed ID: 26393879
[TBL] [Abstract][Full Text] [Related]
37. AIM2 deficiency reduces the development of hepatocellular carcinoma in mice.
Martínez-Cardona C; Lozano-Ruiz B; Bachiller V; Peiró G; Algaba-Chueca F; Gómez-Hurtado I; Such J; Zapater P; Francés R; González-Navajas JM
Int J Cancer; 2018 Dec; 143(11):2997-3007. PubMed ID: 30133699
[TBL] [Abstract][Full Text] [Related]
38. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma.
Ku CY; Liu YH; Lin HY; Lu SC; Lin JY
Oncotarget; 2016 Apr; 7(14):18229-46. PubMed ID: 26919097
[TBL] [Abstract][Full Text] [Related]
39. MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer.
Huang HG; Luo X; Wu S; Jian B
Asian Pac J Cancer Prev; 2015; 16(12):4937-44. PubMed ID: 26163618
[TBL] [Abstract][Full Text] [Related]
40. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
